Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$163.84 - $199.33 $1.39 Million - $1.69 Million
-8,500 Reduced 63.43%
4,900 $967,000
Q1 2024

May 08, 2024

SELL
$159.82 - $182.1 $751,154 - $855,870
-4,700 Reduced 25.97%
13,400 $2.44 Million
Q4 2023

Feb 02, 2024

BUY
$137.6 - $154.97 $811,840 - $914,323
5,900 Added 48.36%
18,100 $2.8 Million
Q3 2023

Oct 26, 2023

BUY
$133.59 - $154.65 $681,309 - $788,715
5,100 Added 71.83%
12,200 $1.82 Million
Q2 2023

Aug 08, 2023

BUY
$132.51 - $164.9 $212,016 - $263,840
1,600 Added 29.09%
7,100 $956,000
Q1 2023

May 02, 2023

SELL
$144.61 - $166.54 $1.61 Million - $1.85 Million
-11,100 Reduced 66.87%
5,500 $876,000
Q4 2022

Jan 03, 2023

BUY
$138.31 - $165.87 $456,423 - $547,371
3,300 Added 24.81%
16,600 $147,000
Q3 2022

Oct 18, 2022

SELL
$134.21 - $153.93 $2.04 Million - $2.34 Million
-15,200 Reduced 53.33%
13,300 $42,000
Q2 2022

Jul 14, 2022

SELL
$137.62 - $174.96 $2.89 Million - $3.67 Million
-21,000 Reduced 42.42%
28,500 $545,000
Q1 2022

Apr 14, 2022

BUY
$131.98 - $163.75 $4.2 Million - $5.21 Million
31,800 Added 179.66%
49,500 $1.2 Million
Q4 2021

Jan 10, 2022

BUY
$107.43 - $135.93 $118,173 - $149,523
1,100 Added 6.63%
17,700 $244,000
Q3 2021

Oct 14, 2021

BUY
$106.4 - $120.78 $542,640 - $615,978
5,100 Added 44.35%
16,600 $29,000
Q1 2021

Apr 29, 2021

BUY
$102.3 - $112.62 $10,230 - $11,262
100 Added 0.88%
11,500 $53,000
Q2 2020

Aug 13, 2020

SELL
$73.37 - $98.18 $220,110 - $294,540
-3,000 Reduced 20.83%
11,400 $144,000
Q1 2020

Apr 09, 2020

BUY
$64.5 - $97.79 $245,100 - $371,602
3,800 Added 35.85%
14,400 $53,000
Q4 2019

Jan 06, 2020

SELL
$72.13 - $90.25 $274,094 - $342,950
-3,800 Reduced 26.39%
10,600 $123,000
Q3 2019

Oct 03, 2019

SELL
$62.98 - $75.72 $491,244 - $590,616
-7,800 Reduced 35.14%
14,400 $97,000
Q4 2018

Jan 03, 2019

BUY
$77.85 - $96.01 $1.73 Million - $2.13 Million
22,200 New
22,200 $33,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Xr Securities LLC Portfolio

Follow Xr Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xr Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Xr Securities LLC with notifications on news.